Nuvectis Pharma Inc (NVCT)
$6.5
Insights on Nuvectis Pharma Inc
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 71.8% return, outperforming this stock by 134.3%
Performance
- $6.35$6.83$6.50
2.31%
Downside
Day's Volatility :7.03%
Upside
4.83%
- $5.85$18.65$6.50
10.0%
Downside
52 Weeks Volatility :68.63%
Upside
65.15%
Returns
| Period | Nuvectis Pharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -35.88% | 0.0% |
6 Months | -21.96% | 0.0% |
1 Year | -62.54% | 0.0% |
3 Years | 101.23% | -22.6% |
Highlights
Market Capitalization | 124.3M |
Book Value | $0.76 |
Earnings Per Share (EPS) | -1.41 |
Wall Street Target Price | 22.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -77.22% |
Return On Equity TTM | -170.23% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -1.41 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.14 |
EPS Estimate Next Year | -1.23 |
EPS Estimate Current Quarter | -0.4 |
EPS Estimate Next Quarter | -0.38 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 238.46%
Technicals Summary
Sell
Neutral
Buy
Nuvectis Pharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Nuvectis Pharma Inc | -13.49% | -21.96% | -62.54% | 101.23% | 101.23% |
 Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
 Regeneron Pharmaceuticals, Inc. | 3.22% | 20.54% | 31.88% | 92.14% | 229.83% |
 Novo Nordisk A/s | 8.85% | 36.12% | 71.83% | 234.04% | 457.53% |
 Vertex Pharmaceuticals Incorporated | 16.81% | 32.76% | 40.6% | 124.79% | 171.36% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Nuvectis Pharma Inc | NA | NA | NA | -1.14 | -1.7 | -0.77 | NA | 0.76 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Nuvectis Pharma Inc | Buy | $124.3M | 101.23% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 229.83% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 457.53% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 171.36% | 29.59 | 39.46% |
Institutional Holdings
BlackRock Inc
2.03%Vanguard Group Inc
1.63%Baldwin Brothers Inc
0.84%Geode Capital Management, LLC
0.73%State Street Corporation
0.70%Northern Trust Corp
0.34%
Company Information
Organization | Nuvectis Pharma Inc |
Employees | 13 |
CEO | Mr. Ron Bentsur M.B.A. |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$6.50
-0.61%
Keyarch Acquisition Corp
$6.50
-0.61%
Connexa Sports Technologies Inc
$6.50
-0.61%
Us Value Etf
$6.50
-0.61%
First Wave Biopharma Inc
$6.50
-0.61%
Global X Msci Next Emerging
$6.50
-0.61%
Fat Projects Acquisition Corp
$6.50
-0.61%
Capital Link Global Fintech
$6.50
-0.61%
Applied Uv Inc
$6.50
-0.61%